Back to results
US 2012/0252736 A1Published application
Methods involving pdgfrbeta inhibitors
AssigneeMedizinische Universitaet Wien
InventorsLukas Kenner, Daniela Laimer
Life of this patent
Estimating the term…
Abstract
The invention refers to PDGFRbeta inhibitor for use in the antiproliferative treatment of T-cell lymphoma, in particular NHL, ALCL and PTCL.
Claims19
-15. (canceled)
A method of treating a patient with T-cell lymphoma and susceptible to a cell proliferative disorder comprising:
- obtaining a PDGFRbeta inhibitor;
- and
- administering the PDGFRbeta inhibitor to the patient.
A method comprising:
- obtaining a PDGFRbeta inhibitor;
- and
- using the PDGFRbeta inhibitor to prepare a pharmaceutical composition useful for treating a patient having T-cell lymphoma and susceptible to a cell proliferative disorder.
Dependencies are inferred from the claim text.